Clinical Trials Sponsored by R-Bio

Total 3842 results

Galderma R&D

Completed

Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis

Psoriasis

United States
Galderma R&D

Completed

Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne

Acne Vulgaris

United States
Galderma R&D

Completed

Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

Plaque Psoriasis

United States
Galderma R&D

Completed

Repeat Insult Patch Test for Daily Advance Cetaphil Moisturizing Lotion

Skin Irritation

United States
Galderma R&D

Completed

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV) (DUAL)

Acne Vulgaris

United States, Puerto Rico
Galderma R&D

Completed

Dose Range Study of CD5789 in Acne Vulgaris

Acne Vulgaris

United States
Galderma R&D

Completed

Comparison Dry Foot Skin Between Diabetic and Non-diabetic Subjects and the Effects of Two Cosmetic Foot Care Products

Xerosis Cutis

Germany
Galderma R&D

Completed

Patient-Reported Outcome Of Facial Erythema (PROOF) (PROOF)

Erythema | Rosacea

United Kingdom, Germany, Sweden
Galderma R&D

Completed

Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer (LOOP)

Foot Dermatoses

Germany
Galderma R&D

Completed

Global Management of Facial Rejuvenation With a New Range of Hyaluronic Acid Dermal Fillers (FRESH)

Facial Wrinkles

France, Germany
Galderma R&D

Completed

Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Rosacea

United States
Galderma R&D

Completed

Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in Acne Vulgaris (FREE)

Acne

Canada
Galderma R&D

Completed

Treatment of Patients With Blepharitis and Facial Rosacea

Dry Eye | Blepharitis | Meibomianitis

United States
Galderma R&D

Completed

PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer

Warts | Actinic Keratosis | Basal Cell Carcinoma | Squamous Cell Carcinoma | Bowens Disease

Denmark, Germany, Norway, Sweden, United Kingdom
Galderma R&D

Completed

Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%

Acne Vulgaris

United States
Galderma R&D

Completed

Phase 3 Papulopustular Rosacea Study

Papulopustular Rosacea

United States, Canada
Galderma R&D

Completed

Performance of Different Application Regimens of ACTINICA® on Protection From UVR-induced Erythema After One Day of Sun Exposure in Fair-skinned Healthy Subjects.

Healthy Subjects, Male or Female, of 18-60 Years Old, With Phototype I, II or III, Not Pre-treated/Pre-protected Skin

France
Galderma R&D

Completed

Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%

Erythematous Rosacea

United States
Galderma R&D

Completed

Comparison of Two Botulinum Toxins Type A on Forehead Wrinkles

Wrinkles

Germany
Galderma R&D

Completed

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Rosacea

United States, Canada
Galderma R&D

Completed

Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp

Actinic Keratosis

United States
Galderma R&D

Completed

Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance (ACCESS II)

Acne

United States, Canada, Puerto Rico
Galderma R&D

Completed

Adjunctive Usage of a Moisturizing Lotion (Cetaphil® Moisturizing Lotion) to Limit the Skin Irritation Linked to the Set-Up of a Treatment by Topical Retinoid (Differin® Gel 0,1%) in Healthy Subjects of Chinese Origins

Healthy Skin

Singapore
Galderma R&D

Completed

Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%

Acne Vulgaris

United States, Canada
Galderma R&D

Completed

Volume Restoration of Plantar Pad With a Hyaluronic Acid Dermal Filler in Metatarsalgia (ELFE)

Metatarsalgia

France
Galderma R&D

Completed

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis

Plaque-type Psoriasis

United States
C. R. Bard

Completed

A Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries

Femoral Artery Occlusion | Femoral Artery Stenosis | Stenosis of Popliteal Arteries | Occlusion of Popliteal Arteries

China
C. R. Bard

Completed

CATERPILLAR™ Arterial Embolization Device Study (CHRYSALIS)

Embolization, Therapeutic

Australia, New Zealand
C. R. Bard

Completed

Korean Post-market Registry Assessing the Clinical Use and Safety of the Lutonix DCB in Femoropopliteal Arteries

Peripheral Artery Disease

Korea, Republic of
C. R. Bard

Completed

LEVANT 2 Safety Registry

Peripheral Artery Disease | Femoropopliteal Artery Occlusion | Femoropopliteal Stenosis

United States
C. R. Bard

Completed

Real-World Registry Assessing the Clinical Use of the Lutonix 035 Drug Coated Balloon Catheter (SAFE-DCB)

Arterial Occlusive Diseases | Peripheral Arterial Disease | Peripheral Vascular Diseases

United States
C. R. Bard

Completed

Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries (LEVANT 2)

Popliteal Artery Stenosis | Popliteal Artery Occlusion | Femoral Artery Occlusion | Femoral Artery Stenosis

United States, Germany, Belgium, Austria
Galderma R&D

Completed

A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)

Canthal Lines
C. R. Bard

Terminated

Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females (CONFIRM) (CONFIRM)

Popliteal Artery Stenosis | Popliteal Artery Occlusion | Femoral Artery Occlusion | Femoral Artery Stenosis

United States
C. R. Bard

Completed

Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries (BTKRegistry)

Peripheral Artery Disease

Austria, Belgium, France, Switzerland, Germany, Italy, Greece, Spain, United Kingdom, Portugal, Saudi Arabia
Galderma R&D

Completed

Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris

Acne Vulgaris

Canada, United States, Germany, Hungary, Puerto Rico
C. R. Bard

Completed

Bard LifeStent and Lutonix DCB for Treatment of Long Lesions in Femoropopliteal Arteries

Peripheral Artery Disease

Germany, Greece, Poland
C. R. Bard

Completed

Lutonix® DCB for Treatment of Long Lesions in Femoropopliteal Arteries

Femoral Artery Occlusion | Femoral Arterial Stenosis

Belgium, Austria, France, Germany, Switzerland
C. R. Bard

Completed

Bard® LifeStent® Vascular Stent Delivery System Study

Peripheral Vascular Disease

Austria, Germany
Galderma R&D

Completed

Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

Acne Vulgaris

United States, Canada
C. R. Bard

Completed

AccuCath™ Intravenous (IV) Device Used by Vascular Access Team (VAT)

Vascular Access Complication

United States
C. R. Bard

Completed

Progel® Pleural Air Leak Sealant (PALS) in Video and Robotic Assisted Thoracoscopic Surgery

Pulmonary Disease

United States
Galderma R&D

Completed

Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.

Acne Vulgaris

Japan
C. R. Bard

Completed

Clinical Evaluation of Ajust™ in Stress Urinary Incontinence (CEASe)

Female Stress Urinary Incontinence

United States
C. R. Bard

Completed

ViVEXX Carotid Revascularization Trial (VIVA)

Carotid Artery Stenosis
C. R. Bard

Terminated

Study of a Urethral Catheter Coated With Eluting Silver Salts (SUCCESS) (SUCCESS)

Catheterization

United States
C. R. Bard

Completed

A Prospective Study of the Performance of the Bard® LifeStent® Vascular Stent Systems (REALITY) (REALITY)

Peripheral Artery Disease

Germany
Unilever R&D

Completed

To Test the Effect of Selected Fibres and Flours in Flat Bread on Post-Prandial Blood Glucose and Insulin Responses in Healthy Indian Population

Healthy

India
C. R. Bard

Terminated

Use and Safety of the LUTONIX® Drug Coated Balloon Catheter in Arteries of the Lower Extremity (LEG)

Peripheral Artery Disease

Malaysia, New Zealand, Canada
C. R. Bard

Completed

Post-Marketing Study to Assess Complication Rates of Oncology Patients With Ports and Peripheral IVs (VEINSFORLIFE)

PORTs/Peripheral IVs Complication Rates

United States

3

Subscribe